
# Title 37 - Patents, Trademarks, and Copyrights
## Chapter I - United States Patent and Trademark Office, Department of Commerce
### Subchapter A - General
#### PART 1 - RULES OF PRACTICE IN PATENT CASES
##### Subpart G - Biotechnology Invention Disclosures
###### Application Disclosures Containing Nucleotide and/or Amino Acid Sequences
####### ยง 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures.
######## see

(d) "Enumeration of its residues" means disclosure of a nucleotide or amino acid sequence in a patent application by listing, in order, each residue of the sequence, where the residues are represented in the manner as defined in paragraph 3(c)(i) or (ii) of WIPO Standard ST.26 (incorporated by reference,ยง 1.839).

(e) "Specifically defined" means any amino acid or nucleotide as defined in paragraph 3(k) of WIPO Standard ST.26.

(f) "Amino acid" includes any D- or L-amino acid or modified amino acid as defined in paragraph 3(a) of WIPO Standard ST.26.

(g) "Modified amino acid" includes any amino acid as described in paragraph 3(e) of WIPO Standard ST.26.

(h) "Nucleotide" includes any nucleotide, nucleotide analog, or modified nucleotide as defined in paragraphs 3(f) and 3(g) of WIPO Standard ST.26.

(i) "Modified nucleotide" includes any nucleotide as described in paragraph 3(f) of WIPO Standard ST.26.

(j) A "Sequence listing XML" must not include any sequences having fewer than 10 specifically defined nucleotides, or fewer than 4 specifically defined amino acids.
